Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1101

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 1101
---
, (iv) 1,000,000 shares issuable pursuant to warrants held by the Bay Shore Trust that are
    immediately exercisable, and (v) 700,000 shares issuable pursuant to warrants held by MIRALOGX LLC, that are immediately exercisable.
    As trustee of the Bay Shore Trust and the Celeste J Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power
    over the shares held by each trust, and, as a result is deemed to have beneficial ownership (as determined under Section 13(d) of
    the Exchange Act) of the securities held by the trusts. The address for MIRALOGX LLC and the Bay Shore Trust is 900 West Platt Street,
    Suite 200, Tampa, Florida, 33606.

DELINQUENT
SECTION 16(A) REPORTS

Section
16(a) of the Exchange Act requires directors and executive officers, and persons who own more than 10% of the Company’s common
stock, to report to the SEC their initial ownership of the Company’s common stock and any subsequent changes in that ownership.
Specific due dates for these reports have been established by the SEC and we are required to disclose in this Annual Report on Form 10-K
any late filings or failures to file.

Based
solely on review of the copies of such reports furnished to us and written representations from reporting persons that no other reports
were required during the fiscal year ended December 31, 2024, we believe that, during the 2023 fiscal year, all of the Company’s
directors and executive officers complied with all Section 16(a) filing requirements applicable to them.

Securities
Authorized for Issuance Under Equity Compensation Plans

The
following table indicates shares of common stock authorized for issuance under our 2022 Omnibus Plan as of December 31, 2024:

    Plan
    category 
    Number
                                            of
                                                                                securities
                                            to be
                                                                                issued
                                            upon exercise
                                                                                of
                                            outstanding
                                                                                options
                                            and warrants  
    Weighted-
                                            average
                                                                                exercise
                                            price of
                                                                                outstanding
                                            options
                                                                                and
                                            warrants  
    Number
                                            of
                                                                                securities
                                                                                remaining
                                            available
                                                                                for
                                            future issuance 
  
    Equity
    compensation plans approved by security holders 
     6,499,236  
    $     2.39